Trial Profile
Efficacy of onabotulinumtoxinA and abobotulinumtoxinA at the conversion ratio of 1:3 in a patients who have asymmetry resulted frm facial palsy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial paralysis
- Focus Therapeutic Use
- 24 Dec 2015 New trial record